Intra Cellular Therapies Stock Return On Equity
| ITCIDelisted Stock | USD 131.87 0.03 0.02% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Intra Cellular's long-term financial health and intrinsic value.
Intra |
Intra Cellular Therapies Company Return On Equity Analysis
Intra Cellular's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Intra Cellular Return On Equity | -0.0858 |
Most of Intra Cellular's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intra Cellular Therapies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Intra Cellular Therapies has a Return On Equity of -0.0858. This is 99.64% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is 72.32% lower than that of the firm.
Intra Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intra Cellular's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intra Cellular could also be used in its relative valuation, which is a method of valuing Intra Cellular by comparing valuation metrics of similar companies.Intra Cellular is currently under evaluation in return on equity category among its peers.
Intra Fundamentals
| Return On Equity | -0.0858 | |||
| Return On Asset | -0.0696 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | (0.15) % | |||
| Current Valuation | 13.06 B | |||
| Shares Outstanding | 106.52 M | |||
| Shares Owned By Insiders | 2.48 % | |||
| Shares Owned By Institutions | 96.40 % | |||
| Number Of Shares Shorted | 2.67 M | |||
| Price To Earning | (6.56) X | |||
| Price To Book | 12.23 X | |||
| Price To Sales | 20.63 X | |||
| Revenue | 680.85 M | |||
| Gross Profit | 387.77 M | |||
| EBITDA | (116.72 M) | |||
| Net Income | (74.68 M) | |||
| Cash And Equivalents | 628.74 M | |||
| Cash Per Share | 6.64 X | |||
| Total Debt | 16.98 M | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 9.81 X | |||
| Book Value Per Share | 10.81 X | |||
| Cash Flow From Operations | (73.18 M) | |||
| Short Ratio | 1.20 X | |||
| Earnings Per Share | (0.73) X | |||
| Target Price | 132.0 | |||
| Number Of Employees | 860 | |||
| Beta | 0.46 | |||
| Market Capitalization | 14.05 B | |||
| Total Asset | 1.37 B | |||
| Retained Earnings | (1.69 B) | |||
| Working Capital | 1.1 B | |||
| Current Asset | 541.82 M | |||
| Current Liabilities | 140.69 M | |||
| Net Asset | 1.37 B |
About Intra Cellular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intra Cellular Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intra Cellular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intra Cellular Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in commodities. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Intra Stock
If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |